More Harms Than Benefits for E-Cigarettes at Population Level
THURSDAY, March 15, 2018 -- Electronic cigarettes (e-cigarettes) are associated with more harm than benefit on a population level, according to a study published online March 14 in PLOS ONE.
Samir Soneji, Ph.D., from the Dartmouth Institute for Health Policy in Lebanon, N.H., and colleagues quantified the benefits and harms associated with e-cigarette use at the population level. The expected years of life gained or lost from the impact of e-cigarette use on smoking cessation was calculated among current smokers, and transition to long-term cigarette smoking among never smokers was assessed for the 2014 U.S. population cohort.
The researchers estimated that use of e-cigarettes in 2014 resulted in 2,070 additional current cigarette-smoking adults aged 25 to 69 years quitting smoking in 2015 (95 percent confidence interval, −42,900 to 46,200) and remaining continually abstinent for at least seven years. The model also estimated that use of e-cigarettes in 2014 would lead to an estimated 168,000 additional never-cigarette-smoking adolescents and young adults aged 12 to 29 years becoming daily smokers at ages 35 to 39 years (95 percent confidence interval, 114,000 to 229,000). Assuming a 95 percent relative harm reduction of e-cigarette use versus cigarette smoking, the model estimated that e-cigarette use in 2014 would lead to 1,510,000 years of life lost (95 percent confidence interval, 920,000 to 2,160,000). The model estimated a greater number of years lost as the relative harm reduction decreased.
"Effective national, state, and local efforts are needed to reduce e-cigarette use among youth and young adults if e-cigarettes are to confer a net population-level benefit in the future," the authors write.
© 2020 HealthDay. All rights reserved.
Posted: March 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.